<DOC>
	<DOCNO>NCT03063749</DOCNO>
	<brief_summary>To observe continued performance Medtronic Resolute Onyxâ„¢ Zotarolimus-Eluting Coronary Stent System real-world more-comer population .</brief_summary>
	<brief_title>RESOLUTE ONYX Post-Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Key Inclusion Criteria Symptomatic coronary artery disease include subject chronic stable angina , silent ischemia , acute coronary syndrome include nonST elevation STelevation myocardial infarction Subject acceptable candidate treatment drug elute stent accordance applicable guideline percutaneous coronary intervention , manufacturer 's Instructions Use , Declaration Helsinki Key Exclusion Criteria Unprotected leave main disease Subjects plan PCI three vessel disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>